(Q46107342)

19 December 2017

title

Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm (English)

1 reference

19 December 2017

1 reference

1 reference

S A Stoch

1

1 reference

19 December 2017

E Friedman

2

1 reference

19 December 2017

A Maes

3

1 reference

19 December 2017

K Yee

4

1 reference

19 December 2017

Y Xu

5

1 reference

19 December 2017

P Larson

6

1 reference

19 December 2017

M Fitzgerald

7

1 reference

19 December 2017

J Chodakewitz

8

1 reference

19 December 2017

J A Wagner

9

1 reference

19 December 2017

publication date

26 February 2009

1 reference

19 December 2017

The Journal of Clinical Pharmacology

published in

1 reference

19 December 2017

volume

49

1 reference

19 December 2017

issue

4

1 reference

19 December 2017

page(s)

398-406

1 reference

19 December 2017

In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270008331133

Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008331133

Influence of food on the pharmacokinetics of ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008331133

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008331133

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008331133

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008331133

Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008331133

Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008331133

Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008331133

Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008331133

Single plasma concentrations of 1'-hydroxymidazolam or the ratio of 1'-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008331133

Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008331133

Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008331133

Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008331133

21 January 2018

Identifiers

DOI

10.1177/0091270008331133

1 reference

19 December 2017

PubMed ID

19246722

1 reference

19 December 2017